Capecitabine in Treating Women With Advanced or Metastatic Breast Cancer

December 17, 2013 updated by: Pharmatech Oncology

A Pilot Trial Of Two Different Doses Of Capecitabine (XELODA) In Patients With Advanced And/Or Metastatic Breast Cancer

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Randomized phase II trial to compare the effectiveness of two different doses of capecitabine in treating women who have advanced or metastatic breast cancer.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

OBJECTIVES:

  • Compare the objective response rate in women with advanced or metastatic breast cancer treated with two dose levels of capecitabine.
  • Compare the duration of response, time to progression, time to treatment failure, survival, incidence of adverse events, and time to onset of the adverse experience in patients treated with this drug.
  • Compare the quality of life of patients treated with this drug.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to Karnofsky performance status (70-80% vs 90-100%) and presence of hepatic metastases (yes vs no). Patients are randomized to one of two treatment arms.

  • Arm I: Patients receive lower-dose oral capecitabine twice daily on days 1-14.
  • Arm II: Patients receive higher-dose oral capecitabine twice daily on days 1-14.

In both arms, courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline, at the end of the third and sixth courses, and at completion of therapy.

PROJECTED ACCRUAL: A total of 120 patients (60 per treatment arm) will be accrued for this study within 9 months.

Study Type

Interventional

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • California
      • Lancaster, California, United States, 93534
        • Antelope Valley Hospital
      • Orange, California, United States, 92868
        • Medical Oncology Care Associates
      • West Covina, California, United States, 91790
        • California Cancer Medical Center
    • Colorado
      • Colorado Springs, Colorado, United States, 80907
        • Oncology Clinic, P.C.
    • Florida
      • Port Saint Lucie, Florida, United States, 34952
        • Hematology Oncology Associates of theTreasure Coast - Port St. Lucie
      • St. Augustine, Florida, United States, 32086
        • North Florida Cancer Center
    • Maryland
      • Baltimore, Maryland, United States, 21236
        • Maryland Hematology/Oncology Associates
    • South Carolina
      • Charleston, South Carolina, United States, 29403
        • Charleston Hematology-Oncology, P.A.
    • Tennessee
      • Collierville, Tennessee, United States, 38017
        • Family Cancer Center
    • Utah
      • Logan, Utah, United States, 84341
        • Logan Regional Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

DISEASE CHARACTERISTICS:

  • Histologically and/or cytologically confirmed breast cancer
  • Advanced and/or metastatic disease

  • At least 1 measurable lesion

    • At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
  • No CNS metastases

  • Hormone receptor status:

    • Not specified

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Sex:

  • Female

Menopausal status:

  • Not specified

Performance status:

  • Karnofsky 70-100%

Life expectancy:

  • At least 12 weeks

Hematopoietic:

  • Neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3

Hepatic:

  • Bilirubin no greater than 1.25 times upper limit of normal (ULN)
  • AST/ALT no greater than 2.5 times ULN (5 times ULN if liver metastases present)
  • Alkaline phosphatase no greater than 2.5 times ULN (5 times ULN if liver metastases present OR 10 times ULN if bone metastases present)
  • No hepatitis

Renal:

  • Creatinine no greater than 1.5 times ULN
  • Creatinine clearance at least 50 mL/min

Cardiovascular:

  • No clinically significant cardiac disease
  • No congestive heart failure
  • No symptomatic coronary artery disease
  • No cardiac arrhythmias poorly controlled with medication
  • No myocardial infarction within the past 12 months even if adequately controlled with medication

Other:

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • HIV negative
  • No severe pain inadequately controlled by analgesics
  • No prior severe and unexpected reaction to fluoropyrimidine therapy
  • No known hypersensitivity to fluorouracil
  • No impaired physical integrity of the upper gastrointestinal tract
  • No malabsorption syndrome
  • No inability to swallow tablets
  • No history of uncontrolled seizures, central nervous system disorder, or psychiatric disability that would preclude study participation
  • No serious uncontrolled infection

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • Not specified

Chemotherapy:

  • At least 2 but no more than 3 prior chemotherapy regimens
  • At least 1 prior chemotherapy regimen containing paclitaxel and an anthracycline as adjuvant therapy or for advanced and/or metastatic disease

Endocrine therapy:

  • Not specified

Radiotherapy:

  • No prior radiotherapy to target lesions unless there is evidence of new disease within the irradiated field
  • No concurrent radiotherapy

Surgery:

  • No prior organ allografts

Other:

  • At least 4 weeks since prior investigational drug
  • No concurrent enrollment on other investigational study
  • No other concurrent anticancer agents

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Pharmatech Oncology

Investigators

  • Study Chair: Sandy Marcus, Pharmatech Oncology

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2001

Study Registration Dates

First Submitted

November 9, 2001

First Submitted That Met QC Criteria

January 26, 2003

First Posted (Estimate)

January 27, 2003

Study Record Updates

Last Update Posted (Estimate)

December 18, 2013

Last Update Submitted That Met QC Criteria

December 17, 2013

Last Verified

April 1, 2004

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CDR0000069030
  • PHARMATECH-XEL-154
  • PHARMATECH-20010330
  • ROCHE-PHARMATECH-XEL-154

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on capecitabine

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe